Cupid Ltd Q4 FY2022 Concall Summary

Key Takeaways

• A year of two halves: FY22 was dragged down by input costs, a delayed South African tender, and a low-margin product mix, but the year-end order book and new IVD vertical set up a materially different FY23.
• Lubricant jelly is the new profit engine: Sales exploded from ₹2.25 crores to ₹25 crores, carrying 40-45% EBITDA margins, and management expects this level to be the new baseline.
• IVD is the big swing factor: The project is 15 months late, regulatory approvals are taking twice as long as expected, and the marketing path is unclear, yet management is shooting for ₹20-30 crores in revenue from FY24 and sees a path to ₹200 crores two years out.
• Order book visibility is strong, but arithmetic is fuzzy: Disclosed orders of ₹209 crores underpin a ₹160 crore FY23 sales projection, though an analyst's math suggests the book could be closer to ₹287 crores, a gap management did not fully reconcile.
• What to watch next quarter: The US FDA 510K submission in June, the Brazil female condom tender outcome, and any concrete IVD contract manufacturing deal that would de-risk the new vertical's ramp-up.

The FY22 Drag: Mix, Costs & A Missing Tender

• Product mix turned adverse: A lower percentage of high-margin female condoms in the sales mix, combined with higher input costs, compressed operating margin from 25% in FY21 to 17% in FY22.
• South Africa tender delay froze a major channel: The three-year tender was due for publication in October 2021 but only materialized in February 2022, pushing the award and subsequent order flow out of the fiscal year and directly hurting reported performance.
• UNFPA provided a bright spot: Record sales of ₹50 crores to UNFPA, supplying 38 countries, made it Cupid's top customer for the first time, partially offsetting weakness elsewhere.

Lubricant Jelly: The High-Margin Breakout

• Scale arrived suddenly: Lubricant jelly sales jumped from ₹2.25 crores in FY21 to ₹25 crores in FY22, driven by procurement agencies and UNFPA agents who now view personal lubricants as a favorable companion product to condoms.
• Margins are structurally attractive: The product carries a 40-45% EBITDA margin, and management projects this can reach 45-50% in FY23, making it a disproportionate contributor to profitability as volumes hold.
• Capacity is not a constraint: The facility has ~21 crore pieces of annual capacity and ran at 95% utilization on only two of three shifts for eight months, so significant headroom exists without new capex. A recently added microbiology lab reinforces Cupid's position as one of only four or five WHO pre-qualified suppliers globally.
• Geographic reach is broadening: Sales extended beyond Africa into Mongolia, Ukraine, Romania, Georgia, the Middle East, the Caribbean, the Philippines, and Papua New Guinea, suggesting demand is not a single-region story.
• India entry unlocks a new market: Cupid received FDA India permission to market its lubricant jelly domestically for the first time, becoming only the second or third company in the country to do so.

Garg: "On one hand, we are careful about expanding too fast without realizing and without consolidating our marketing situation for the new production, but at the same time, we are looking at new business verticals."

IVD: The Delayed, High-Potential Second Act

• The project lost 15 months: Construction was completely stalled during Corona with no activity or workers available, and the regulatory process that was expected to take six months has more than doubled to about 12 months due to extensive requirements and slower processing by the Drug Controller and local FDA offices.
• Licensing is progressing, slowly: Cupid has received the manufacturing license for five IVD products and expects to achieve licenses for the next products by August. ISO 13485 certification is at an advanced stage and expected in the next couple of months, which will then enable the CE license application for European market access.
• Commercial operations are imminent: Management plans to start commercial operations in H2 FY23, from September onwards, with a revenue target of approximately ₹20-30 crores starting from FY24.
• Contract manufacturing could de-risk the ramp: Cupid is in negotiations with a Singapore pharmaceutical company to manufacture five of their patented products, a deal that could absorb at least 50% of installed IVD capacity if successful.
• The marketing path is genuinely unknown: Management explicitly stated it does not know what direction IVD marketing will take and expects it will take about the next 12 months to see a clear picture in terms of revenues and profits.
• The ambition is large: Management hopes IVD sales will exceed ₹200 crores two years from now, a figure that would transform the company's scale if achieved.

Garg: "The requirement are quite extensive and both the Drug Controller office and the local FDA offices, they have informed with additional work resulting in much slower processing for our applications. There were some of the reasons which were beyond our control, and we could not have forecasted neither the Corona '19 consequences, nor the procedural delay and the regulatory requirements of the Drug Controller of India."

Order Book & FY23 Revenue Bridge

• FY23 sales projection anchored at ₹160 crores: This is built from the current order book and expected dispatches, with management also projecting net profit after tax of ₹32-35 crores for the year.
• The disclosed order book stands at ₹209 crores: This figure, stated as of April 2022, includes a ₹65 crore Tanzania order received in late March and a South African tender order of over ₹100 crores announced in February.
• An analyst's math suggests a larger number: Per an analyst's calculation, the order book should be approximately ₹287 crores after accounting for the last press release figure of ₹141 crores, subtracting ₹31 crores in deliveries, and adding announced wins of ₹12 crores (UNFPS), ₹100 crores (South Africa), and ₹65 crores (Tanzania). Management attributed the difference to dispatches in April and May and the timing of the April 2022 reference date, but the arithmetic gap was not fully reconciled.
• Female condom orders are stacking up: A confirmed order is already in hand, a new Brazil tender expected in June could add ₹25-30 crores (not yet in the FY23 projection), and a South African female condom order of ₹68 crores begins supply from end of June.
• Lubricant jelly provides a steady base: Management expects at least ₹25 crores in FY23 lubricant sales, with orders of about ₹15-20 crores anticipated throughout the remaining year until March.
• Q1 FY23 will be top-line heavy but margin-light: Sales of ₹30-40 crores are expected, but profitability will not be proportionate because female condom dispatches only start in June.

Strategic Shifts: CEO, Buyback & Stake Sale

• CEO search has been reset: The search was originally for one individual with contraceptive market expertise, international marketing, and financial background. The decision to add IVD as a vertical has changed the requirements, delaying the process, and management now seeks someone with an extensive IVD background plus export marketing capability for condoms and lubricants.
• A buyback is under preliminary exploration: An expert committee is looking into a buyback program, with amounts discussed ranging from ₹20 crores to ₹80 crores. The decision must account for larger working capital requirements for both condoms and IVD, and the final outcome remains unknown.
• Founder stake sale talks are live: Management confirmed it has been approached about a potential sale of its stake in Cupid and is open to reasonable suggestions, characterizing the gap between expectation and offer as within 15% to 20% of the numbers.
• Next vertical is already in sight: Cupid is looking at women's sexual health related products as the next line of business, seeing a very attractive market in India and overseas.

Garg: "Before last year we are looking for one individual who had expertise in the contraceptive markets who also had some international marketing and also some financial background as CEO. But now with the decision to add another vertical to our business line in terms of IVD, our focus has changed now in terms of the requirements for CEO which has delayed this process somewhat."

US FDA & The Next Growth Catalyst

• The 510K submission is imminent: Cupid has finished the South African pregnancy study and expects to submit the 510K application to the US FDA in the early part of June.
• The timeline points to an April 2023 commercial start: Management expects the FDA to take six to nine months to comment on the application, and if successful, commercial activities in the US could begin from April 2023 onwards.
• Male condom capacity expansion is on hold: Management is cautious about expanding too fast, citing a big Malaysian manufacturer that increased capacity to over 300 crore pieces but sold only 60%, resulting in losses. The priority is consolidating the marketing situation for existing production while pursuing new verticals.

Guidance & Commitments

Key Metrics